

Resource Summary Report

Generated by [RRID](#) on Sep 3, 2026

TCCSUP

RRID:CVCL_1738

Type: Cell Line

Proper Citation

RRID:CVCL_1738

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1738

Proper Citation: RRID:CVCL_1738

Description: Cell line TCCSUP is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Bladder carcinoma

Defining Citation: [PMID:571047](#), [PMID:836756](#), [PMID:3518877](#), [PMID:3708594](#), [PMID:6220172](#), [PMID:6244232](#), [PMID:6582512](#), [PMID:6823318](#), [PMID:6826254](#), [PMID:7787250](#), [PMID:9850064](#), [PMID:11416159](#), [PMID:11668190](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:24018021](#), [PMID:24035680](#), [PMID:24367658](#), [PMID:25984343](#), [PMID:25997541](#), [PMID:26055179](#), [PMID:27270441](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29732388](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: UBC-40 urothelial bladder cancer cell line index., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: BLA-40 bladder carcinoma cell line panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: TCCSUP

Synonyms: TCCSuP, TCC-SUP, TCC Sup

Cross References: BTO:BTO_0006308, CLO:CLO_0009283, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-5,

BioGRID_ORCS_Cell_line:450, BioSample:SAMN03472747, BioSample:SAMN03473325, BioSample:SAMN10988046, cancercellines:CVCL_1738, CCRID:3101HUMSCSP571, Cell_Model_Passport:SIDM01190, ChEMBL-Cells:ChEMBL3307466, ChEMBL-Targets:ChEMBL615010, CLS:305073, Cosmic:687459, Cosmic:755398, Cosmic:925833, Cosmic:943734, Cosmic:1046692, Cosmic:1285131, Cosmic:1286003, Cosmic:2037961, Cosmic:2050466, Cosmic:2057460, Cosmic:2444246, Cosmic:2685942, Cosmic-CLP:687459, DepMap:ACH-000720, DSMZ:ACC-377, DSMZCellDive:ACC-377, EGA:EGAS00001000978, GDSC:687459, GEO:GSM136227, GEO:GSM142308, GEO:GSM142311, GEO:GSM142312, GEO:GSM827282, GEO:GSM888783, GEO:GSM1374955, GEO:GSM1374956, GEO:GSM1574563, GEO:GSM1670526, Hysigen:TCH-C356, IARC_TP53:3724, LiGeA:CCLE_887, LINCS_LDP:LCL-1720, PharmacDB:TCCSUP_1570_2019, PRIDE:PXD030304, Progenetix:CVCL_1738, PubChem_Cell_line:CVCL_1738, Wikidata:Q54971867

ID: CVCL_1738

Record Creation Time: 20220427T221621+0000

Record Last Update: 20260830T000100+0000

Ratings and Alerts

No rating or validation information has been found for TCCSUP.

No alerts have been found for TCCSUP.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Jin Z, et al. (2026) HOXB4 Promotes Bladder Cancer Progression in Part Through Transcriptional Activation of Smoothened. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 40(1), e71388.

Iskender B, et al. (2026) Reprogramming-driven Proteomic Shifts Mirror Bladder Cancer Progression and Reveal Biomarker Candidates Across Disease Grades. Cancer genomics & proteomics, 23(4), 777.

Guo D, et al. (2026) The Physicochemical Synergy Effect of Nanosecond Pulsed Electric Fields (nsPEF) and cisplatin on reversing chemoresistance of bladder cancer. PloS one, 21(4), e0346699.

Iskender B, et al. (2026) Conjoining cell reprogramming and mass spectrometry to identify the proteomic variations in the reprogrammed bladder cancer cells: finding cues of

normalisation. BMC cancer, 26(1).

Pece A, et al. (2026) Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker. Molecular oncology, 20(3), 823.

Shi Y, et al. (2026) piR-43452 suppresses bladder cancer progression and enhances gemcitabine sensitivity via GTSF1/PIWIL4-mediated LRP1 mRNA destabilization. Translational oncology, 63, 102626.

Yu K, et al. (2026) Lactylation enhances YTHDF3 stability to promote cisplatin resistance via m6A-dependent KDM6B decay in bladder cancer. Cancer letters, 642, 218282.

Stuckey JI, et al. (2026) Covalent PPAR γ inverse agonism by FX-909 reveals mechanistic insights into therapeutic targeting of PPAR γ /RXR γ -activated urothelial carcinoma. Cell chemical biology, 33(6), 837.

Wang X, et al. (2025) PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway. Cancer discovery, 15(3), 633.

Hernández-Prat A, et al. (2024) Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors. Molecular oncology.

Klümper N, et al. (2023) PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma. Oncoimmunology, 12(1), 2267744.

Wang Y, et al. (2022) Development of Novel Aptamer-Based Targeted Chemotherapy for Bladder Cancer. Cancer research, 82(6), 1128.

Athans S, et al. (2022) STAG2 expression is associated with adverse survival outcomes and regulates cell phenotype in muscle-invasive bladder cancer. Cancer research communications, 2(10), 1129.

Lu YT, et al. (2022) FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer. Cancers, 14(7).

Fu G, et al. (2022) Activation of cGAS-STING Signal to Inhibit the Proliferation of Bladder Cancer: The Immune Effect of Cisplatin. Cells, 11(19).

Vanoni G, et al. (2021) Human primed ILCPs support endothelial activation through NF- κ B signaling. eLife, 10.

Jiang G, et al. (2021) The Clinical Implications and Molecular Mechanism of CX3CL1 Expression in Urothelial Bladder Cancer. Frontiers in oncology, 11, 752860.

Wang L, et al. (2021) Immunosuppression Induced by Glutamine Deprivation Occurs via Activating PD-L1 Transcription in Bladder Cancer. Frontiers in molecular biosciences, 8, 687305.

Moose DL, et al. (2020) Cancer Cells Resist Mechanical Destruction in Circulation via RhoA/Actomyosin-Dependent Mechano-Adaptation. Cell reports, 30(11), 3864.

Kim S, et al. (2019) Epigenetic regulation of mammalian Hedgehog signaling to the stroma determines the molecular subtype of bladder cancer. *eLife*, 8.